GenSight Biologics S.A.
GSGTF
$0.19
-$0.05-20.79%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -76.10% | -18.66% | 18.54% | -2.18% | -27.10% |
| Total Other Revenue | -35.63% | -35.18% | -33.67% | -40.89% | -46.42% |
| Total Revenue | -52.08% | -28.24% | -11.36% | -26.27% | -39.95% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -52.08% | -28.24% | -11.36% | -26.27% | -39.95% |
| SG&A Expenses | -30.19% | -45.71% | -54.33% | -47.99% | -41.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.18% | -37.30% | -43.51% | -40.44% | -37.50% |
| Operating Income | 23.62% | 38.20% | 46.72% | 41.88% | 37.24% |
| Income Before Tax | 24.43% | 37.79% | 46.66% | 37.02% | 27.68% |
| Income Tax Expenses | 134.38% | 856.25% | -- | 322.58% | -48.39% |
| Earnings from Continuing Operations | 24.40% | 37.74% | 46.58% | 36.99% | 27.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.40% | 37.74% | 46.58% | 36.99% | 27.68% |
| EBIT | 23.62% | 38.20% | 46.72% | 41.88% | 37.24% |
| EBITDA | 15.69% | 34.25% | 44.94% | 43.28% | 41.73% |
| EPS Basic | 63.16% | 69.51% | 73.09% | 56.57% | 41.34% |
| Normalized Basic EPS | 63.19% | 69.56% | 73.13% | 56.57% | 41.33% |
| EPS Diluted | 63.16% | 69.51% | 73.09% | 56.57% | 41.34% |
| Normalized Diluted EPS | 63.19% | 69.56% | 73.13% | 56.57% | 41.33% |
| Average Basic Shares Outstanding | 77.81% | 86.31% | 98.10% | 71.75% | 44.20% |
| Average Diluted Shares Outstanding | 77.81% | 86.31% | 98.10% | 71.75% | 44.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |